Form 4 for ELTX Elicio Therapeutics, Inc.
Accepted 2026-02-03 00:00:00 ET · period of report 2026-02-02 · accession 0001601485-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-03 | 2026-02-02 | ELTX | Connelly Robert | CEO, Pres, Dir | A - Grant | $0.00 | +73.6K | 120.6K | +157% | $0 |
| D | 2026-02-03 | 2026-02-02 | ELTX | Connelly Robert | CEO, Pres, Dir | A - Grant | $0.00 | +147.2K | 147.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | A | A | 73,600 | $0.00 | 120,570 | D | — | — | (F1) Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-02 | A | A | 147,200 | $0.00 | 147,200 | D | $8.10 · — to 2036-02-02 | 147,200 Common Stock | (F2) The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |